Denali Therapeutics
Stock Forecast, Prediction & Price Target
Denali Therapeutics Financial Estimates
Denali Therapeutics Revenue Estimates
Denali Therapeutics EBITDA Estimates
Denali Therapeutics Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $48.66M N/A | $108.46M 122.89% | $330.53M 204.74% | Avg: $106.65M Low: $61.83M High: $216.27M avg. -67.73% | Avg: $263.82M Low: $149.30M High: $505.82M avg. 147.35% | Avg: $445.38M Low: $252.05M High: $853.93M avg. 68.81% | Avg: $759.60M Low: $429.87M High: $1.45B avg. 70.54% |
Net Income
% change YoY
| $-290.58M N/A | $-325.99M -12.18% | $-145.22M 55.45% | Avg: $-464.19M Low: $-456.07M High: $-179.95M avg. -219.64% | Avg: $-394.53M Low: $-471.18M High: $-89.29M avg. 15.00% | Avg: $-129.95M Low: $-284.91M High: $-56.62M avg. 67.06% | Avg: $124.18M Low: $54.10M High: $272.27M avg. 195.56% |
EBITDA
% change YoY
| $-295.75M N/A | $-330.36M -11.70% | $-179.97M 45.52% | Avg: $-71.62M Low: $-145.23M High: $-41.52M avg. 60.20% | Avg: $-177.16M Low: $-339.67M High: $-100.26M avg. -147.35% | Avg: $-299.08M Low: $-573.44M High: $-169.26M avg. -68.81% | Avg: $-510.09M Low: $-978.00M High: $-288.67M avg. -70.54% |
EPS
% change YoY
| -$2.39 N/A | -$2.6 -8.78% | -$1.06 59.23% | Avg: -$2.74 Low: -$3.32 High: -$1.31 avg. -158.11% | Avg: -$2.12 Low: -$3.43 High: -$0.65 avg. 22.44% | Avg: -$0.95 Low: -$2.07 High: -$0.41 avg. 55.41% | Avg: $0.9 Low: $0.39 High: $1.98 avg. 195.56% |
Operating Expenses
% change YoY
| $344.41M N/A | $449.20M 30.42% | $527.23M 17.36% | Avg: $99.03M Low: $57.41M High: $200.82M avg. -81.21% | Avg: $244.98M Low: $138.63M High: $469.70M avg. 147.35% | Avg: $413.57M Low: $234.05M High: $792.95M avg. 68.81% | Avg: $705.35M Low: $399.17M High: $1.35B avg. 70.54% |
FAQ
What is Denali Therapeutics stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 14.49% in 2025-2028.
We have gathered data from 12 analysts. Their low estimate is -456.07M, average is -464.19M and high is -179.95M.
What is Denali Therapeutics stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 54.74% in 2025-2028.
We have gathered data from 11 analysts. Their low revenue estimate is $61.83M, average is $106.65M and high is $216.27M.
What is Denali Therapeutics stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 28.82% in 2025-2028.
We have gathered data from 12 analysts. Their low earnings per share estimate is -$3.32, average is -$2.74 and high is $-1.31.
What is the best performing analyst?
In the last twelve months analysts have been covering Denali Therapeutics stock. The most successful analyst is Michael Yee.